Novo Nordisk will almost certainly launch with: A savings card for patients with commercial insurance (reducing costs to $25$50/month in many cases) A patient assistance program for income-qualifying uninsured patients Possible direct-to-consumer pricing through NovoCare Pharmacy, similar to Wegovys $349/month self-pay model
I am not sure about this finding but maybe its an evidence of decreased scar tissue and increased type 1 collagen
Baar MP, Brandt RM, Putavet DA, Klein JD, Derks KW, Bourgeois BR, et al
The addition of an N-terminal C20 fatty acid on cagrilintide prolongs the half-life of this medication compared to the first-generation drug, pramlintide
Semax has multiple delivery forms and they are not interchangeable: intranasal and subcutaneous routes differ in absorption, dose, and clinical use